PRESS RELEASES

Date Title and Summary View
Toggle Summary Regulus Therapeutics Presents Additional Data from its Autosomal Dominant Polycystic Kidney Disease (ADPKD) Program at PKD Connect 2021
Study demonstrates clinical proof of mechanism with statistically significant increases in polycystin levels following RGLS4326 treatment in the first cohort of patients with ADPKD Trends indicate further increases in polycystin levels may be achievable with longer term and, potentially, less
View HTML
Toggle Summary Regulus Therapeutics to Present Additional Data from its Autosomal Dominant Polycystic Kidney Disease (ADPKD) Program at PKD Connect 2021
SAN DIEGO , June 21, 2021 /PRNewswire/ --  Regulus Therapeutics Inc .  (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today announced that it will present new preclinical data and
View HTML
Toggle Summary Regulus Therapeutics Announces Incremental Update of Autosomal Dominant Polycystic Kidney Disease (ADPKD) Program
Data to Be Presented Today at the Oppenheimer Rare & Orphan Disease Summit SAN DIEGO , May 21, 2021 /PRNewswire/ --  Regulus Therapeutics Inc.  (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or
View HTML
Toggle Summary Regulus Therapeutics to Present at the Oppenheimer Rare & Orphan Disease Summit
SAN DIEGO , May 14, 2021 /PRNewswire/ --  Regulus Therapeutics Inc.  (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs ("Regulus"), today announced that Jay Hagan , President and Chief Executive Officer of Regulus, will
View HTML
Toggle Summary Regulus Therapeutics Reports First Quarter 2021 Financial Results and Recent Updates
Regulus Therapeutics Demonstrates Target Engagement in First-Ever Study of RGLS4326 in Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD) Second Cohort Underway with Data Expected Mid-2021 SAN DIEGO , May 13, 2021 /PRNewswire/ --  Regulus Therapeutics Inc.
View HTML
Toggle Summary Regulus Therapeutics Announces Timing for First Quarter 2021 Financial Results Webcast and Conference Call
SAN DIEGO , May 6, 2021 /PRNewswire/ --  Regulus Therapeutics Inc .  (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), announced today that it will report financial results and highlights
View HTML
Toggle Summary Regulus Therapeutics Announces Top-Line Data from the First Cohort of Phase 1b Clinical Trial of RGLS4326 for the Treatment of Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Demonstrated Pharmacokinetic Profile Similar to Healthy Volunteers Statistically Significant Increase in Polycystin 1 Biomarker Observed by End of Study Data Presentation Targeted for American Society of Nephrology (ASN) Kidney Week Regulus Therapeutics to Host Conference Call Today at 8:30 a.m.
View HTML
Toggle Summary Regulus Therapeutics Announces Completion of Dosing in the First Cohort of Phase 1b Clinical Trial of RGLS4326 for the Treatment of Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD)
LA JOLLA, Calif. , April 15, 2021 /PRNewswire/ --  Regulus Therapeutics Inc .  (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today announced that it completed dosing in the first cohort
View HTML
Toggle Summary Regulus Therapeutics to Present at the 20th Annual Needham Virtual Healthcare Conference
LA JOLLA, Calif. , April 7, 2021 /PRNewswire/ --  Regulus Therapeutics Inc .  (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs ("Regulus"), today announced that Jay Hagan , President and Chief Executive Officer of
View HTML
Toggle Summary Regulus Therapeutics Reports Fourth Quarter and Year-End 2020 Financial Results and Recent Updates
Completed Enrollment in First Cohort of Phase 1b Clinical Trial of RGLS4326 for the Treatment of Patients with Autosomal Dominant Polycystic Kidney Disease ("ADPKD") Closed $19M Private Financing LA JOLLA, Calif. , March 9, 2021 /PRNewswire/ --  Regulus Therapeutics Inc.
View HTML